These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26592960)

  • 41. Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma.
    Stecca BA; Nardo B; Chieco P; Mazziotti A; Bolondi L; Cavallari A
    J Hepatol; 1997 Aug; 27(2):337-45. PubMed ID: 9288609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis.
    Mavropoulos JC; Cuchacovich M; Llanos C; Aguillón JC; Gatica H; Pizzo SV; Gonzalez-Gronow M
    J Rheumatol; 2005 Nov; 32(11):2116-24. PubMed ID: 16265688
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
    Juillerat-Jeanneret L
    J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy.
    Filippon L; Vanzin CS; Biancini GB; Pereira IN; Manfredini V; Sitta A; Peralba Mdo C; Schwartz IV; Giugliani R; Vargas CR
    Mol Genet Metab; 2011 Jun; 103(2):121-7. PubMed ID: 21420339
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quaternary benzo[c]phenanthridine alkaloids as inhibitors of dipeptidyl peptidase IV-like activity baring enzymes in human blood plasma and glioma cell lines.
    Sedo A; Malík R; Vicar J; Simánek V; Ulrichová J
    Physiol Res; 2003; 52(3):367-72. PubMed ID: 12790770
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI.
    Lin HY; Chuang CK; Chen MR; Lin SM; Hung CL; Chang CY; Chiu PC; Tsai WH; Niu DM; Tsai FJ; Lin SJ; Hwu WL; Lin JL; Lin SP
    Mol Genet Metab; 2016 Apr; 117(4):431-7. PubMed ID: 26899310
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA damage in leukocytes from pretreatment mucopolysaccharidosis type II patients; protective effect of enzyme replacement therapy.
    Filippon L; Wayhs CA; Atik DM; Manfredini V; Herber S; Carvalho CG; Schwartz IV; Giugliani R; Vargas CR
    Mutat Res; 2011 Apr; 721(2):206-10. PubMed ID: 21334454
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD26/dipeptidyl peptidase IV: a comparative study of healthy persons and kidney transplant recipients before and early after transplantation.
    Leicht S; Shipkova M; Klett C; Gert H; Altrock E; Wilhelm J; Bolley R; Wollmeyer J; Ender A; Luz B; Olbricht C; Wieland E
    Clin Biochem; 2013 Oct; 46(15):1383-8. PubMed ID: 23608353
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease.
    Sun AL; Deng JT; Guan GJ; Chen SH; Liu YT; Cheng J; Li ZW; Zhuang XH; Sun FD; Deng HP
    Diab Vasc Dis Res; 2012 Oct; 9(4):301-8. PubMed ID: 22388283
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases.
    Cuchacovich M; Gatica H; Pizzo SV; Gonzalez-Gronow M
    Clin Exp Rheumatol; 2001; 19(6):673-80. PubMed ID: 11791639
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD26/DPP IV in experimental and clinical organ transplantation.
    Korom S; de Meester I; Belyaev A; Schmidbauer G; Schwemmle K
    Adv Exp Med Biol; 2003; 524():133-43. PubMed ID: 12675233
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elevated Dipeptidyl Peptidase IV (DPP-IV) Activity in Plasma from Patients with Various Lysosomal Diseases.
    Ługowska A; Baydakova G; Ilyushkina A; Zakharova E; Mierzewska H; Szymańska K; Wierzba J; Kubalska J; Graban A; Kmieć T; Perkowska-Sumiła B; Tylki-Szymańska A; Bednarska-Makaruk M
    Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33669444
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome).
    Papadia F; Lozupone MS; Gaeta A; Capodiferro D; Lacalendola G
    Eur Rev Med Pharmacol Sci; 2011 Mar; 15(3):253-8. PubMed ID: 21528770
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
    Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
    Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the susceptibility of porcine and human dipeptidyl-peptidase IV to inhibition by protein-derived peptides.
    Lacroix IM; Li-Chan EC
    Peptides; 2015 Jul; 69():19-25. PubMed ID: 25828735
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic activity in patients with pancreatic ductal adenocarcinoma.
    Busek P; Vanickova Z; Hrabal P; Brabec M; Fric P; Zavoral M; Skrha J; Kmochova K; Laclav M; Bunganic B; Augustyns K; Van Der Veken P; Sedo A
    Pancreatology; 2016; 16(5):829-38. PubMed ID: 27320722
    [TBL] [Abstract][Full Text] [Related]  

  • 57. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
    Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of Idursulfase therapy in patients with Mucopolysaccharidosis type II who initiated enzyme replacement therapy in adult age. A systematic review of the literature.
    Pérez-López J; Moltó-Abad M; Muñoz-Delgado C; Morales-Conejo M; Ceberio-Hualde L; Del Toro M
    Mol Genet Metab; 2018 Jul; 124(3):216-227. PubMed ID: 29801985
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Susceptibility of milk protein-derived peptides to dipeptidyl peptidase IV (DPP-IV) hydrolysis.
    Nongonierma AB; FitzGerald RJ
    Food Chem; 2014 Feb; 145():845-52. PubMed ID: 24128555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Untargeted LC-HRMS metabolomics reveals candidate biomarkers for mucopolysaccharidoses.
    Torres CL; Scalco FB; de Oliveira MLC; Peake RWA; Garrett R
    Clin Chim Acta; 2023 Feb; 541():117250. PubMed ID: 36764508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.